The crowdfunding campaign is about to reach the objective of 100,000€. At the moment, 96,622 € have been raised, with the participation of 39 investors. Once finished the campaign, investors will participate in Iproteos with a 5.14% of the offered shares by Iproteos. This campaign is aimed to the obtaining of funding for the completition of the non-regulatory preclinical studies for the new schizophrenia treatment, IPR19. Iproteos has other two lines of research, one for Parkinson disease, and another one for epilepsia. Do you want to be our investor number 40? Hurry up!